Resumo
Definição
História e exame físico
Principais fatores diagnósticos
- presença de fatores de risco
- assintomático
- polidipsia
- poliúria
Outros fatores diagnósticos
- infecções por cândida
- infecções cutâneas
- infecções do trato urinário
- fadiga
- visão turva
- polifagia
- perda de peso não intencional
- parestesias
- acantose nigricans
Fatores de risco
- idade avançada
- sobrepeso/obesidade
- diabetes gestacional
- hiperglicemia não diabética
- história familiar de diabetes do tipo 2
- ascendência não branca
- síndrome do ovário policístico
- hipertensão
- dislipidemia
- doença cardiovascular
- estresse
Investigações diagnósticas
Primeiras investigações a serem solicitadas
- glicemia de jejum
- HbA1c
- glicemia 2 horas após sobrecarga com ingesta de 75 g de glicose
- glicemia plasmática aleatória
Investigações a serem consideradas
- perfil lipídico em jejum
- cetonúria
- relação entre albumina e creatinina (RAC)
- creatinina sérica e taxa de filtração glomerular (TFG) estimada
- eletrocardiograma (ECG)
- índice de pressão tornozelo-braquial (ITB)
- peptídeo C aleatório
- testagem de autoanticorpos
- testes da função hepática
Algoritmo de tratamento
no diagnóstico inicial
HbA1C acima da meta: não gestante
HbA1C acima do limite acordado na farmacoterapia inicial ou alterações de risco cardiovascular: não gestante
gestante
Colaboradores
Autores
Surya Rajeev, MBBS, MRCP, MD
Consultant Physician and Clinical Director
Department of Diabetes and Endocrinology
Liverpool University Hospital NHS Foundation Trust
UK
Declarações
SR has received reimbursement from Novo Nordisk for conferences, and has presented paid lectures.
Agradecimentos
Dr Surya Rajeev would like to gratefully acknowledge Dr Partha Kar, Dr Amar Puttanna, Dr Patrick J. O'Connor and Dr JoAnn M. Sperl-Hillen, the previous contributors to this topic.
Declarações
PK has sat on advisory boards and attended events reimbursed by Novo Nordisk, Eli Lilly, and Sanofi. AP has received honoraria from Napp, Novo Nordisk, Sanofi, Lilly-Boehringer Ingelheim, Daiichi-Sankyo, and AstraZeneca for presentation at meetings, conference registration, or participating in advisory boards. PJO receives research funding from the National Institutes of Health on multiple projects and is an author of a number of references cited in this topic. JMS-H is an author of a number of references cited in this topic and is an inventor on a US patent for Disease Treatment Simulation, a simulation-based technology developed without commercial support to educate health providers on chronic disease management in a virtual environment.
Revisores
Vinod Patel, MD, FRCP, FHEA, MRCGP, DRCOG, MBChB, BSc (Hons), RCPathME
Professor, Diabetes and Clinical Skills
Warwick Medical School
University of Warwick
Hon Consultant in Endocrinology and Diabetes, Acute Medicine, Medical Obstetrics
Diabetes and Endocrinology Centre
George Eliot Hospital NHS Trust
Nuneaton
Clinical Director for Diabetes West Midlands Clinical Networks & Clinical Senate
NHS England and NHS Improvement - Midlands
UK
Declarações
VP declares he has worked with most of the large pharmaceutical industry groups over the years with the majority of the work being in education of healthcare professionals in diabetes care. This includes Novo Nordisk, Eli Lily, MSD, BI, Sanofi, Napp, Internis, Takeda, and AZ. VP has been part of advisory board work on occasions. VP has received conference arrangements and lecture fees. VP is a trustee of the charity South Asian Health Foundation.
Gregory Lip, MD, FRCP, DFM, FACC, FESC, FEHRA
Price-Evans Professor of Cardiovascular Medicine
University of Liverpool
Senior Investigator
National Institute for Health Research
UK
Distinguished Professor
Faculty of Medicine
Aalborg University
Denmark
Adjunct Professor
Yonsei University
Seoul
South Korea
Declarações
GL has acted as a consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, and Daiichi-Sankyo.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
Referências
Principais artigos
National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. Jun 2022 [internet publication].Texto completo
Marx N, Federici M, Schütt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023 Oct 14;44(39):4043-140.Texto completo Resumo
National Institute for Health and Care Excellence. Diabetes in pregnancy: management from preconception to the postnatal period. Dec 2020 [internet publication].Texto completo
Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022 Nov 1;45(11):2753-86.Texto completo Resumo
Artigos de referência
Uma lista completa das fontes referenciadas neste tópico está disponível para os usuários com acesso total ao BMJ Best Practice.
Diagnósticos diferenciais
- Hiperglicemia não diabética (pré-diabetes)
- Diabetes mellitus, tipo 1
- Diabetes autoimune latente do adulto (LADA)
Mais Diagnósticos diferenciaisDiretrizes
- 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes
- Management of hyperglycaemia in type 2 diabetes, 2022
Mais DiretrizesFolhetos informativos para os pacientes
Diabetes do tipo 2: devo tomar insulina?
Diabetes: o que posso fazer para me manter saudável?
Mais Folhetos informativos para os pacientesCalculadoras
Probabilidade de cirrose na hepatite C (FIB-4)
Taxa de filtração glomerular estimada pela equação CKD-EPI
Mais Calculadoras
Conectar-se ou assinar para acessar todo o BMJ Best Practice
O uso deste conteúdo está sujeito ao nosso aviso legal